2,2'-dipyrazinylmethane | 130017-97-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,2'-dipyrazinylmethane
• 英文别名: dpzm；di-2-pyrazinylmethane；2-(Pyrazin-2-ylmethyl)pyrazine
• CAS: 130017-97-9
• 化学式: C₉H₈N₄
• 分子量: 172.189
• InChiKey: SZWQRTQSJUSYPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3-二氯吡嗪 、 2,2'-dipyrazinylmethane 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 32.5h， 以58%的产率得到5-(pyrazin-2-yl)-pyrrolo[1,2-a:4,5-b]pyrazine
  参考文献：
  名称：

  Fused pyrazino[2,3-b]indolizine and indolizino[2,3-b]quinoxaline derivatives; synthesis, structures, and properties

  摘要：

  The synthesis of six new compounds incorporating either a pyrazino[2,3-b]indolizine or indolizino[2,3-b] quinoxaline core are reported in good yield (58-87%). The intermediates for the key cyclization reaction for one set of compounds (5a-c), with a sterically demanding 3,5-dimethylpyrazole group in the 5-position of the core, were found to be mono-substituted. These intermediates could be isolated and cyclized by heating under acid-catalyzed conditions. To further demonstrate the versatility of the chemistry, compounds 6a-c were synthesized in 58-68% yields. Compounds 5a-c are non-planar in solution and the solid-state, while 6a-c have close to planar conformations, pointing to weak hydrogen bonds between the acidic C-Hs and the adjacent azine nitrogen atoms. The cytotoxicity of the six newly synthesized and three previously prepared compounds was assessed against a human glioblastoma multiforme cell line. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.09.133
• 作为产物：
  描述：

  吡嗪-2-羧酸甲酯 在 一水合肼 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙二醇 为溶剂， 生成 2,2'-dipyrazinylmethane
  参考文献：
  名称：

  Fused pyrazino[2,3-b]indolizine and indolizino[2,3-b]quinoxaline derivatives; synthesis, structures, and properties

  摘要：

  The synthesis of six new compounds incorporating either a pyrazino[2,3-b]indolizine or indolizino[2,3-b] quinoxaline core are reported in good yield (58-87%). The intermediates for the key cyclization reaction for one set of compounds (5a-c), with a sterically demanding 3,5-dimethylpyrazole group in the 5-position of the core, were found to be mono-substituted. These intermediates could be isolated and cyclized by heating under acid-catalyzed conditions. To further demonstrate the versatility of the chemistry, compounds 6a-c were synthesized in 58-68% yields. Compounds 5a-c are non-planar in solution and the solid-state, while 6a-c have close to planar conformations, pointing to weak hydrogen bonds between the acidic C-Hs and the adjacent azine nitrogen atoms. The cytotoxicity of the six newly synthesized and three previously prepared compounds was assessed against a human glioblastoma multiforme cell line. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.09.133

文献信息

• [EN] 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS<br/>[FR] DÉRIVÉS D'ACIDE 2-(TERT-BUTOXY)-2-(7-MÉTHYLQUINOLÉIN-6-YL)ACÉTIQUE POUR TRAITER LE SIDA
  申请人：GILEAD SCIENCES INC

  公开号：WO2013103724A1

  公开（公告）日：2013-07-11

  The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.

  本发明提供作为d的化合物及其盐。本发明还提供包括本文所披露的化合物的药物组合物，用于制备本文所披露的化合物的方法，用于制备本文所披露的化合物的有用中间体，以及使用本文所披露的化合物治疗HIV感染、治疗HIV病毒的增殖、治疗艾滋病或延缓哺乳动物发生艾滋病或ARC症状的治疗方法。
• Exploring the Use of Structure and Polymer Incorporation to Tune Silver Ion Release and Antibacterial Activity of Silver Coordination Polymers
  作者：Rosemary J. Young、Stephanie L. Begg、Campbell J. Coghlan、Christopher A. McDevitt、Christopher J. Sumby

  DOI：10.1002/ejic.201800640

  日期：2018.8.15

  Rosemary J. Young, Stephanie L. Begg, Campbell J. Coghlan, Christopher A. McDevitt and Christopher J. Sumby

  Rosemary J. Young、Stephanie L. Begg、Campbell J. Coghlan、Christopher A. McDevitt 和 Christopher J. Sumby
• Probing Solid‐State Breathing and Structural Transformations in a Series of Silver(I) Porous Coordination Polymers
  作者：Witold M. Bloch、Christopher J. Sumby

  DOI：10.1002/ejic.201500647

  日期：2015.8

  Key observations of the role anions and solvents play in the solid-state flexibility of a series of isostructural silver(I) porous coordination polymers (PCPs) are reported. Building upon earlier results for the perchlorate salt, the structural transformations of two new analogues of a 3D PCP [Ag(dpzm)]X (1) (dpzm = 2,2′-dipyrazinylmethane; X = PF6, ClO4, BF4), which contain either PF6 (1a) or BF4

  报告了阴离子和溶剂在一系列同结构银 (I) 多孔配位聚合物 (PCP) 的固态柔韧性中的作用的关键观察结果。基于高氯酸盐的早期结果，3D PCP [Ag(dpzm)]X (1)（dpzm = 2,2'-二吡嗪基甲烷；X = PF6、ClO4、BF4）的两个新类似物的结构转变，其中PF6 (1a) 或 (1c) 反离子，进行了研究。这些材料经历了显着的客体诱导单晶到单晶 (SC-SC) 固态收缩和膨胀，X 射线晶体学可以准确地阐明这一点。PCP 1a-1c 的呼吸程度与其 3D 结构中包含的阴离子类型和溶剂客体的性质有关。使用 X 射线衍射，进一步揭示了这组材料在去溶剂化时发生的结构转变。这些研究表明，虽然合成的形式（包含 DMSO）在去溶剂化时会发生转变（多孔 3D 到密堆积 3D；多孔 3D 到 2D），但溶剂交换形式更稳定。
• COMPOSITION AND LIGHT-EMITTING ELEMENT COMPRISING THE COMPOSITION
  申请人：Akino Nobuhiko

  公开号：US20100038592A1

  公开（公告）日：2010-02-18

  Disclosed is a composition comprising a compound having a pyrazine ring structure and a phosphorescent compound, wherein the compound having a pyrazine ring structure has a pyrazine ring structure represented by the general formula (1), (2) or (3): wherein R and R 1 independently represent a hydrogen atom or a univalent group and multiple R's and multiple R 1 's may be the same as or different from one another. Also disclosed is a polymer having a residue derived from the phosphorescent compound and the pyrazine ring structure.

  本发明公开了一种化合物组合物，包括具有吡嗪环结构的化合物和磷光化合物，其中具有吡嗪环结构的化合物具有由通式（1）、（2）或（3）表示的吡嗪环结构：其中R和R1分别独立表示氢原子或一价基团，多个R和多个R1可以相同或不同。本发明还公开了一种聚合物，其具有源自磷光化合物和吡嗪环结构的残基。
• 3, 6-BICYCLOLIDES
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：EP1830858A2

  公开（公告）日：2007-09-12